Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Myelodysplastic-Myeloproliferative Diseases

ClinicalTrials.gov lists 690 trials for Myelodysplastic-Myeloproliferative Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 54.

MeSH D054437 Hemic and Lymphatic Diseases C15 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 192 Phase 1/2 Phase 1/2 93 Phase 2 Phase 2 246 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 51 Phase 4 Phase 4 1 Not applicable Not applicable 46 Observational Observational 56 Phase 1 Phase 1 192 Phase 1/2 Phase 1/2 93 Phase 2 Phase 2 246 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 51 Phase 4 Phase 4 1 Not applicable Not applicable 46 Observational Observational 56

Trials per phase (log scale)

1 more section with rows

200 of the 690 trials are tagged with Myelodysplastic-Myeloproliferative Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Myelodysplastic-Myeloproliferative Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Myelodysplastic-Myeloproliferative Diseases trials start? (36)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 33

1991: 2 trials (Observational 1, Phase 2 1) 1992: 2 trials (Phase 2 2) 1993: 2 trials (Phase 3 1, Phase 2 1) 1994: 2 trials (Phase 2 2) 1995: 4 trials (Phase 2/3 1, Phase 2 2, Phase 1/2 1) 1996: 10 trials (Observational 2, Phase 3 2, Phase 2 4, Phase 1 2) 1997: 10 trials (Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 4) 1998: 23 trials (Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 8) 1999: 27 trials (Observational 1, Not applicable 3, Phase 3 2, Phase 2 7, Phase 1/2 3, Phase 1 11) 2000: 21 trials (Not applicable 2, Phase 3 4, Phase 2 3, Phase 1/2 5, Phase 1 7) 2001: 23 trials (Not applicable 1, Phase 3 2, Phase 2 12, Phase 1/2 3, Phase 1 5) 2002: 30 trials (Not applicable 4, Phase 3 5, Phase 2 9, Phase 1/2 3, Phase 1 9) 2003: 32 trials (Observational 2, Not applicable 5, Phase 3 2, Phase 2 13, Phase 1/2 4, Phase 1 6) 2004: 31 trials (Observational 2, Not applicable 5, Phase 3 2, Phase 2 11, Phase 1/2 2, Phase 1 9) 2005: 31 trials (Observational 2, Not applicable 3, Phase 3 2, Phase 2 14, Phase 1/2 1, Phase 1 9) 2006: 33 trials (Observational 3, Not applicable 2, Phase 3 1, Phase 2 16, Phase 1/2 5, Phase 1 6) 2007: 29 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 10, Phase 1/2 1, Phase 1 10) 2008: 31 trials (Observational 7, Not applicable 1, Phase 3 6, Phase 2 7, Phase 1/2 3, Phase 1 7) 2009: 22 trials (Other 1, Observational 7, Not applicable 2, Phase 3 2, Phase 2 4, Phase 1/2 3, Phase 1 3) 2010: 26 trials (Observational 5, Not applicable 4, Phase 3 1, Phase 2 9, Phase 1/2 2, Phase 1 5) 2011: 13 trials (Observational 1, Phase 4 1, Phase 3 1, Phase 2 6, Phase 1/2 1, Phase 1 3) 2012: 19 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 9, Phase 1 6) 2013: 22 trials (Observational 1, Not applicable 2, Phase 3 1, Phase 2 9, Phase 1/2 6, Phase 1 3) 2014: 11 trials (Observational 1, Phase 2 5, Phase 1/2 3, Phase 1 2) 2015: 13 trials (Observational 2, Phase 2 8, Phase 1/2 2, Phase 1 1) 2016: 12 trials (Phase 2 5, Phase 1/2 2, Phase 1 5) 2017: 20 trials (Observational 1, Not applicable 1, Phase 3 2, Phase 2 6, Phase 1/2 4, Phase 1 6) 2018: 26 trials (Observational 1, Phase 3 1, Phase 2 11, Phase 1/2 4, Phase 1 9) 2019: 21 trials (Not applicable 1, Phase 2 4, Phase 1/2 6, Phase 1 10) 2020: 23 trials (Phase 3 1, Phase 2/3 1, Phase 2 7, Phase 1/2 4, Phase 1 10) 2021: 23 trials (Phase 3 1, Phase 2/3 1, Phase 2 10, Phase 1/2 5, Phase 1 6) 2022: 20 trials (Observational 2, Phase 3 1, Phase 2 4, Phase 1/2 5, Phase 1 8) 2023: 21 trials (Not applicable 2, Phase 3 1, Phase 2 5, Phase 1/2 4, Phase 1 9) 2024: 13 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 3, Phase 1/2 3, Phase 1 3) 2025: 20 trials (Observational 3, Phase 2 10, Phase 1/2 2, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 15
2025 20
2024 13
2023 21
2022 20
2021 23
2020 23
2019 21
2018 26
2017 20

Showing 10 of 36 earlier years.

Start your 14-day trial Email me all 36 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 18 trials starting in 2026 and about 18 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 74 trials still running at the 2026-10-09 snapshot; registered median of 46 months across 505 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Myelodysplastic-Myeloproliferative Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 192
Phase 1/2 93
Phase 2 246
Phase 2/3 4
Phase 3 51
Phase 4 1
Not applicable 46
Observational 56
Unknown 1

How many Myelodysplastic-Myeloproliferative Diseases trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 6
Recruiting 81
Enrolling by invitation 1
Active, not recruiting 45
Completed 406

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Myelodysplastic-Myeloproliferative Diseases trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 54
Children's Oncology Group 13
European Organisation for Research and Treatment of Cancer - EORTC 8

Which drugs are being tested for Myelodysplastic-Myeloproliferative Diseases? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 113
Busulfan 73

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 120
Azacitidine MTD 81
Peripheral blood stem cell transplantation 81
Mofetil Mycophenolate 69
IR Tacrolimus 65

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Myelodysplastic-Myeloproliferative Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 670 58
Pneumonia 418 34
Neutrophil count decreased 318 15
Anemia 290 21
Death 287 26

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Myelodysplastic-Myeloproliferative Diseases? (16)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study. Blood advances 2023 Yes
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leukemia 2022 Yes
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes. BMC cancer 2022 Yes
Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. Leukemia & lymphoma 2019 Yes
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American journal of hematology 2018 Yes

Showing 5 of 16 publications.

Start your 14-day trial Email me all 16 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Myelodysplastic/myeloproliferative disease Annual incidence 1-9 / 1 000 000 Europe Not stated Unspecified
Myelodysplastic/myeloproliferative disease Annual incidence 1-9 / 1 000 000 Europe Not stated Exact
Myelodysplastic/myeloproliferative disease Annual incidence 1-9 / 1 000 000 Europe Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Myelodysplastic/myeloproliferative disease 98275 Exact Orphanet Rare Disease Ontology (ORDO)
Myelodysplastic/myeloproliferative disease 98275 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (3)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages